AC Immune S.A.
NASDAQ:ACIU · NASDAQ Global Market
+$0.04 today
Vol 0.21M · Avg 0.32M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-156.8%
avg -31.7%
ROIC
-113.9%
avg -27.0%
ROA
-45.6%
avg -18.1%
Analysis
ROA is currently the strongest return metric at -45.6% versus its period average of -18.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Andrea Pfeifer | Co-Founder, Chief Executive Officer & Director | $1.52M | — | 69 | $3.82M | 3.75% |
Matthias Maurer | Senior Vice President & General Counsel | — | — | 44 | — | — |
Mark Danton | Executive Vice President of Information Systems & Artificial Intelligence | — | — | 62 | — | — |
Julien Rongere | Senior Vice President of Regulatory Affairs & Quality Assurance | — | — | 48 | — | — |
Günther Staffler | Executive Vice President of Development | — | — | 57 | — | — |
Francesca Capotosti | Senior Vice President of Research | — | — | — | — | — |
Gary Anthony Waanders | Senior Vice President of Investor Relations & Corporate Communications | — | — | 62 | — | — |
Oliver Sol | Vice President & Head of Clinical Development | — | — | 58 | — | — |
Christopher Roberts | Chief Financial Officer & Vice President of Finance | — | — | 36 | $155,382.00 | 0.15% |
Piergiorgio Donati | Chief Operating Officer | — | — | 55 | $0.00 | <0.01% |
Bojana Portmann | SVP of Intellectual Property,Intellectual Property & Business Development | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
3
$90,785.00
Net Sentiment
$90,785.00
Net selling
Most Active
Pfeifer Andrea
3 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| May 15, 2026 | Pfeifer Andrea Direct | Sell | 10.0K | $2.79 | $27,935.00 | |
| Apr 15, 2026 | Pfeifer Andrea Direct | Sell | 10.0K | $3.14 | $31,425.00 | |
| Apr 15, 2026 | Pfeifer Andrea Direct | Sell | 10.0K | $3.14 | $31,425.00 |
Analysis
Insiders reported 0 buys worth $0.00 and 3 sells worth $90,785.00 over the last 12 months. That adds up to net selling of $90,785.00. Pfeifer Andrea was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -12.5% | +14.4% (13yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -12.5% over three years. Forward estimates point to Revenue at +14.4% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Alpha Tau Medical Ltd.
NASDAQ:DRTS
$863.06M
Alto Neuroscience, Inc.
NYSE:ANRO
$786.10M
Annexon, Inc.
NASDAQ:ANNX
$593.79M
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
$441.85M
Amarin Corporation plc
NASDAQ:AMRN
$334.75M
Silence Therapeutics plc
NASDAQ:SLN
$327.10M
Cellectis S.A.
NASDAQ:CLLS
$306.27M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$292.98M
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
$116.72M
Mereo BioPharma Group plc
NASDAQ:MREO
$50.38M
Who manages ACIU?
AC Immune S.A. (ACIU) lists 11 active executives. The top listed executive is Matthias Maurer, Senior Vice President & General Counsel.
Are ACIU insiders buying or selling?
Recent insider activity shows net buying of $527,828.44.
Explore More
Continue the stock analysis
Jump to another research area for this company.